Red cell transfusion thresholds for preterm infants: finally some answers

Edward F Bell

Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA

Correspondence to
Dr Edward F Bell, Pediatrics, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa 52240, USA; edward-bell@uiowa.edu

Received 31 December 2020
Revised 2 March 2021
Accepted 25 March 2021
Published Online First 27 April 2021

ABSTRACT

Extremely low birthweight infants become anaemic during their care in the neonatal intensive care unit because of the physiological anaemia experienced by all newborn infants compounded by early umbilical cord clamping, blood loss by phlebotomy for laboratory monitoring and delayed erythropoiesis. The majority of these infants receive transfusions of packed red blood cells, usually based on haemoglobin values below a certain threshold. The haemoglobin or haematocrit thresholds used to guide transfusion practices vary with infant status and among institutions and practitioners. Previous smaller studies have not given clear guidance with respect to the haemoglobin thresholds that should trigger transfusions or even if this is the best way to decide when to transfuse an infant. Two large clinical trials of similar design comparing higher and lower haemoglobin thresholds for transfusing extremely low birthweight infants were recently published, the ETNO and TOP trials. These trials found reassuringly conclusive and concordant results. Within the range of haemoglobin transfusion thresholds studied, there was no difference in the primary outcome (which was the same in both studies), neurodevelopmental impairment at 2 years’ corrected age or death before assessment, in either study. In addition, there was no difference in either study in either of the components of the primary outcome. In conclusion, haemoglobin transfusion thresholds within the ranges used in these trials, 11–13 g/dL for young critically ill or ventilated infants and 7–10 g/dL for stable infants not requiring significant respiratory support, can be safely used without expecting adverse consequences on survival or neurodevelopment.

INTRODUCTION

The haemoglobin level at birth is higher than in later life because of the need to compensate for the relatively low arterial oxygen tension in the fetus. After birth, the haemoglobin falls as red cells die faster than they are replaced. This physiological anaemia occurs in all infants over the first months of life.1 In preterm infants, the physiological anaemia is exacerbated by early clamping of the umbilical cord, blood loss by phlebotomy for laboratory monitoring and delayed erythropoiesis, leading to the anaemia of prematurity.2 Extremely low birthweight (ELBW) infants, those with birth weights below 1000 g, experience the greatest degree of anaemia. Although other measures have been tried to reduce the need for transfusing ELBW infants,2–4 more than 80% of these infants are transfused with red blood cells (RBCs) during their initial hospitalisation.5 6 19 20 This review will address haemoglobin thresholds and other measures used in deciding when to provide top-up transfusions of 10–20 mL/kg of RBCs to ELBW infants.

BACKGROUND

Haemoglobin level as transfusion trigger

A variety of measures besides haemoglobin level have been proposed to guide RBC transfusion decisions for ELBW infants. These measures, including circulating RBC volume,7 fractional oxygen extraction8 9 and blood lactic acid,10 have not been adopted in clinical practice for several reasons; RBC volume and fractional oxygen extraction are not easily measured and, hence, not widely available, and lactic acidemia is a late sign of anaemia that many prefer to avoid. Measurement of cerebral oxygenation by near-infrared spectroscopy has shown promise,11–14 but this method requires further evaluation before it can be applied as a clinical tool to aid in transfusion decisions.

Use of the haemoglobin or haematocrit to guide RBC transfusion decisions has been standard practice in neonatology for decades, and the use of transfusion guidelines has been shown to decrease transfusions in neonatal units.3 5 6 19 20 The use of haemoglobin thresholds to guide transfusion decisions is based on the fact that haemoglobin concentration is one of the main determinants of systemic oxygen transport, along with cardiac output and arterial oxygen saturation, and the main goal of top-up transfusions is to avoid tissue hypoxia and the resultant end-organ injury. Until recently, there was no definitive guidance on the choice of transfusion thresholds17 18 based on the published randomised clinical trials (table 1).5 6 19 20 Iowa and PINT trials

The Iowa3 and PINT6 (Premature Infants in Need of Transfusion) trials both varied their transfusion thresholds with postnatal age and/or respiratory status. The two trials used similar haemoglobin (or haematocrit) transfusion thresholds for their lower threshold groups, but the transfusion thresholds for the higher group were higher in the Iowa trial, 15.3 g/dL (haematocrit 46%) for ventilated patients compared with 13.5 g/dL for higher group infants in the PINT trial receiving respiratory support in the first week. The corresponding thresholds for the lower haemoglobin threshold groups were similar, 11.3 g/dL (haematocrit 34%) and 11.5 g/dL for the Iowa and PINT trials, respectively. For convalescing infants without respiratory support, the higher haemoglobin thresholds were 10.0 g/dL (hematocrit 30%) for the Iowa trial and 8.5 g/dL for
the PINT trial; the lower haemoglobin thresholds were 7.3 g/dL (haematocrit 22%) for the Iowa trial and 7.5 g/dL for the PINT trial.

In terms of early outcomes, the Iowa and PINT trials found no clear difference between lower and higher haemoglobin transfusion thresholds except for fewer transfusions with lower transfusion thresholds in both trials and more frequent apnoea with lower transfusion thresholds in the Iowa trial. However, both trials found intriguing hints of possible neurological effects from maintaining the haemoglobin at different levels. The Iowa trial revealed more frequent severe cranial ultrasound abnormalities among the lower threshold infants in an unplanned post hoc analysis but, paradoxically, smaller brain volumes and poorer cognitive delay in the lower threshold group became significant.

**ETTNO and TOP trials**

In view of the continuing lack of definitive guidance for choosing transfusion thresholds for ELBW infants and the need for more information about the impact of early haemoglobin levels on brain development, two large randomised trials were undertaken, and the results of these trials have been recently published.²⁴ ²³

**ETTNO trial**

The ETTNO (Effects of Transfusion Thresholds on Neurocognitive Outcomes of Extremely Low-Birth-Weight Infants) trial²⁴ enrolled 1013 infants in 36 European centres between 2011 and 2014; 96.4% of the infants were enrolled at 32 centres in Germany. The patients had birth weights between 400 and 1000 g and gestational ages of 29 weeks or less. They were randomly assigned within 72 hours of birth to higher or lower haematocrit transfusion thresholds, which varied with postnatal age and health status, critical or noncritical (table 2).

These thresholds were applied throughout the infant’s hospital stay. The primary outcome was neurodevelopmental impairment at 2 years or death before assessment. Neurodevelopmental

**Table 1** Randomised trials published before 2020 comparing higher and lower haemoglobin transfusion thresholds for preterm infants

<table>
<thead>
<tr>
<th>Transfusion threshold group</th>
<th>Iowa trial²⁴</th>
<th>PINT trial²⁵</th>
<th>Taiwan trial²⁶</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highest haemoglobin threshold,* g/dL</td>
<td>Higher</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Lowest haemoglobin threshold, g/dL</td>
<td>15.3</td>
<td>11.3</td>
<td>13.5</td>
</tr>
<tr>
<td>No of subjects</td>
<td>51</td>
<td>49</td>
<td>228</td>
</tr>
<tr>
<td>Mean gestational age, weeks</td>
<td>28</td>
<td>28</td>
<td>26</td>
</tr>
<tr>
<td>Mean haemoglobin, t g/dL</td>
<td>11.0</td>
<td>8.3</td>
<td>11.2</td>
</tr>
<tr>
<td>Mean no of transfusions</td>
<td>5.2</td>
<td>3.3‡</td>
<td>5.7</td>
</tr>
<tr>
<td>Mean no of RBC donor exposures</td>
<td>2.8</td>
<td>2.2</td>
<td>2.6</td>
</tr>
<tr>
<td>Infants never transfused, %</td>
<td>12</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Died, %</td>
<td>2</td>
<td>4</td>
<td>18</td>
</tr>
</tbody>
</table>

*Thresholds varied with postnatal age and/or respiratory support; haematocrit thresholds converted to haemoglobin levels by dividing by 3.

†Mean haemoglobin levels at age 6 weeks in Iowa trial, at age 4 weeks in PINT trial and at day 30 in Taiwan trial.

‡Statistically significant difference, higher vs lower, p<0.05.

**Table 2** Haemoglobin transfusion thresholds and primary outcome for ETTNO and TOP trials

<table>
<thead>
<tr>
<th>Study</th>
<th>ETTNO trial²⁴</th>
<th>TOP trial²⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfusion threshold group</td>
<td>Higher</td>
<td>Lower</td>
</tr>
<tr>
<td>Severity stratum</td>
<td>Critical</td>
<td>Non-critical</td>
</tr>
<tr>
<td>Haemoglobin threshold,* g/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 1</td>
<td>13.7</td>
<td>11.7</td>
</tr>
<tr>
<td>Weeks 2–3 (ETTNO) or 2 (TOP)</td>
<td>12.3</td>
<td>10.3</td>
</tr>
<tr>
<td>Week &gt;3 (ETTNO) or ≥3 (TOP)</td>
<td>11.3</td>
<td>9.3</td>
</tr>
<tr>
<td>Primary outcome</td>
<td>Neurodevelopmental impairment† at 2 years’ corrected age or death before assessment</td>
<td>Neurodevelopmental impairment† at 2 years’ corrected age or death before assessment</td>
</tr>
</tbody>
</table>

*Thresholds varied with postnatal age and/or degree of illness; haematocrit thresholds were converted to haemoglobin levels by dividing by 3.

†Neurodevelopmental impairment defined as any of the following: (1) cognitive deficit, defined as Bayley-II Mental Developmental Index (MDI) score <85; (2) cerebral palsy, defined according to the Surveillance of Cerebral Palsy in Europe network; (3) moderate or severe visual or hearing impairment, defined as corrected visual acuity of <6/60 and/or need for hearing aid or cochlear implant.

‡Statistically significant difference, higher vs lower, p<0.05.

§Neurodevelopmental impairment defined as any of the following: (1) cognitive delay, defined as Bayley-III composite cognitive score <85; (2) moderate or severe cerebral palsy, defined as Level II or higher on the Gross Motor Function Classification System; (3) severe vision loss, defined as corrected visual acuity in the better eye of <20/200; or (4) severe hearing impairment, defined as bilateral hearing loss requiring hearing aids or cochlear implants.
improvement was defined as any of the following: (1) cognitive deficit, defined as Bayley-II MDI score <85 or inability to be tested because of severe impairment, score on another cognitive test more than 1 SD below the mean, or paediatrician’s assessment of cognitive deficit; (2) cerebral palsy; (3) severe visual or hearing impairment, defined as best-corrected visual acuity of less than 20/200 and/or hearing loss requiring hearing aid or cochlear implant. Several secondary outcomes were also recorded. The study was powered to detect a 10% difference in the primary outcome. The primary outcome was ascertained for 928 infants (91.6%), a nearly equal percentage in both treatment groups. The rate of the primary outcome, neurodevelopmental impairment or death before assessment, was not significantly different between groups: 44.4% in the higher threshold group and 42.9% in the lower threshold group (table 3). There were also no significant differences in secondary outcomes, including the components of the primary outcome.

**TOP trial**

The TOP (Transfusion of Prematures) trial25 enrolled 1824 infants between 2012 and 2017. The study was conducted in 19 centres (41 hospitals) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. The patients had birth weights of 1000 g or less and gestational ages of 22 through 28 weeks. They were randomly assigned within 48 hours of birth to higher or lower haemoglobin transfusion thresholds, which varied with postnatal age and whether the infant was receiving respiratory support (table 2). These thresholds were applied throughout the infant’s hospital stay. The primary outcome was neurodevelopmental impairment at 2 years (22–26 months’ corrected age) or death before assessment. Neurodevelopmental impairment was defined as any of the following: (1) cognitive delay, defined as Bayley-III composite cognitive score <85; (2) moderate or severe cerebral palsy, defined as Level II or higher on the Gross Motor Function Classification System26; (3) severe vision loss or hearing impairment, defined as corrected visual acuity in the better eye of less than 20/200 and/or hearing loss requiring hearing aid or cochlear implant. A number of secondary outcomes were also recorded. The study was powered to detect a 7% difference in the primary outcome. The primary outcome was ascertained for 1692 infants (92.8%, a nearly equal percentage in both treatment groups). The rate of the primary outcome, neurodevelopmental impairment or death before assessment, was not significantly different between groups: 50.1% in the high threshold group and 49.8% in the low threshold group (table 3). There were also no significant differences in secondary outcomes, including the components of the primary outcome.

**WHAT WE HAVE LEARNED FROM THE ETTNO AND TOP TRIALS**

Rarely are we treated to two large, well-designed trials being published within weeks of each other that show identical and conclusive results, as with the ETTNO and TOP trials. We now know that, within the bounds of the transfusion thresholds used in these trials, there is no evidence of any advantage for ELBW infants to a policy of maintaining higher haemoglobin levels in the first weeks of life by using higher haemoglobin or haemato-crit transfusion thresholds. In particular, there is no evidence to date of any neurological advantage to having higher haemoglobin levels. Of course, we cannot rule out the possibility that even higher haemoglobin levels, as targeted in the higher threshold
group in the Iowa and Taiwan transfusion trials, might confer an advantage; however, this possibility seems remote and is not likely to ever be tested in a large trial. We should also reserve the possibility that an advantage in brain development may not be apparent until 2 years but might be evident later. The TOP study infants are now being examined at school age to investigate this possibility. Similarly, lower haemoglobin levels than those tested in the ETNO and TOP trials have not been adequately tested and might be harmful.

It is important to note that despite more frequent transfusions in the higher haemoglobin threshold groups in these trials, there was no difference in the rates of necrotising enterocolitis (NEC). The NEC rates in the ETNO trial were similar in the higher and lower threshold groups, 5.3% and 6.2%, respectively; in the TOP trial, these rates were higher but equal between groups, 10.0% and 10.5% in the higher and lower threshold groups, respectively (Table 3). This finding that NEC was not more frequent in the groups with more transfusions may be explained by the fact that the transfusion thresholds, even in the lower threshold groups, were not low enough to precipitate the gut ischemia–reperfusion responses postulated by Patel et al and others as the mechanism for transfusion-associated NEC. It must be acknowledged, however, that neither trial was specifically powered to examine the impact of transfusion thresholds on the risk of NEC. There were also no differences between the higher and lower threshold groups in either study in the rates of patent ductus arteriosus, severe retinopathy of prematurity, severe intraventricular haemorrhage or periventricular leucomalacia, or bronchopulmonary dysplasia (Table 3).

One advantage to using lower haemoglobin thresholds to guide transfusion practice is a reduction in the number of transfusions given to infants. In both trials, the infants in the higher threshold group received more transfusions, 2.9 versus 1.7 in the ETNO trial and 6.2 versus 4.4 transfusions per infant for the higher and lower threshold groups, respectively, in the TOP trial (Table 3).

Our ultimate goal should be to avoid transfusions altogether whenever possible. Not surprisingly, both the ETNO and TOP trials found more infants were never transfused in their lower threshold groups, but overall, far more infants were able to avoid transfusion in the ETNO trial. In the ETNO trial, 21% and 40% of infants were never transfused in the higher and lower threshold groups, respectively; in the TOP trial, the corresponding figures were 3% and 11%. This raised the question of why the US babies were so much less able to avoid transfusion in both groups. The subjects’ mean birth weights (750 g) and gestational ages (26 weeks) were similar in the two trials. An interesting difference in umbilical cord management at birth may partly explain the difference in the percentages of infants who avoided transfusion altogether. In the ETNO trial, 63% and 61% of infants in the higher and lower threshold groups had delayed cord clamping at birth; the corresponding figures for the TOP trial were only 27% and 24% (Table 3). The numbers did not differ between transfusion threshold groups in either trial. The mortality rates were higher in the TOP trial, suggesting that the subjects in this trial may have been sicker. Consequently, there may also have been differences in phlebotomy losses between the ETNO and TOP trials, although phlebotomy losses were not reported for either trial. Erythropoiesis-stimulating agents were not allowed in either trial.

Fortunately, neither of these trials, ETNO or TOP, was confounded by the problem seen in the SUPPORT oxygen saturation targeting trial, where there was no difference in the composite outcome of retinopathy of prematurity or death, but the component outcomes were both significant, although in opposite directions, presenting a dilemma to clinicians. In both the ETNO and TOP trials, there was no difference between the transfusion threshold groups in the rates of death, neurodevelopmental impairment at 2 years or the composite primary outcome.

What might be the theoretical harmful consequences of going beyond the thresholds used in these studies? Higher thresholds could increase the risk of hyperviscosity after transfusion, which could compromise blood flow and oxygen delivery to the brain and other organs. Adverse effects on brain size and neurocognitive function were found at school age in a small cohort of children from the higher haemoglobin threshold group in the Iowa transfusion trial, where a haemoglobin transfusion threshold of 15.3 g/dL was used for ventilated infants. On the other hand, transfusion thresholds below those used in the lower threshold groups in the ETNO and TOP trials might risk tissue hypoxia in the brain and elsewhere and might place patients at increased risk of transfusion-associated NEC if they are transfused.

SUMMARY

Unless information to the contrary emerges from the school-age examinations of the TOP trial infants, practitioners should be comfortable using transfusion thresholds within the ranges used in the ETNO and TOP trials (Table 2). This means that haemoglobin transfusion thresholds should not be above 13 g/dL or below 11 g/dL for infants in the first week of life who are critically ill or require significant respiratory support and should not be above 10 g/dL or below 7 g/dL for stable, older infants who are not critically ill or require significant respiratory support. Using the lower thresholds, 11 g/dL for critically ill infants and 7 g/dL for stable infants, will reduce transfusions, conserving blood for needier patients and reducing transfusion-associated risks. The burden of proving safety falls to anyone who proposes using higher or lower thresholds than the ones studied in these two large clinical trials. Delayed cord clamping at birth, measures to minimise phlebotomy blood losses and good nutritional practices are also important means of limiting the need for blood transfusion. In time, we may have better tools to make individualised decisions about a preterm infant’s need for transfusion.

Funding EFB received funding from the NICHD (UG1 HD053109) and the NHLBI (U01 HL112776) for his participation in the TOP trial.

Competing interests EFB was the co-principal investigator of the TOP trial.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Data availability statement No data are available.

ORCID iD Edward F Bell http://orcid.org/0000-0002-5568-0889

REFERENCES

Review


16 Baer VL, Henry E, Lambert DK, et al. Implementing a program to improve compliance with neonatal intensive care unit transfusion guidelines was accompanied by a reduction in transfusion rate: a pre–post analysis within a multihospital health care system. Transfusion 2011;51:264–9.


